0111 GMT - UBS cuts its price target on Sonic Healthcare by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. "The structure of the German system suggests diagnostic providers will be disadvantaged," UBS says. "We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify." UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 10, 2026 20:11 ET (01:11 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.